PDLIM7 and myeloid sarcoma: In support of the epidemiological data, it has been described that MS patients show increased levels of serum or plasma IgG antibodies against the EBNA family in general, and in particular against EBNA 1, EBNA2 (20), EBNA3 (EBNA3A), EBNA4 (EBNA3B), EBNA6 (EBNA3C), LMP1, EBV capsid protein VP26 (21), early antigen complex (20, 22) EBV viral capsid antigen (23), and the EBV lytic protein BRRF2 (24).